R&D Ecosystem - Sunshine Lake Pharma Co., Ltd.

R&D Ecosystem Innovation Achievements Artificial Intelligence

R&D Innovation

R&D Ecosystem Innovation Achievements Artificial Intelligence

R&D Overview

Sunshine Lake Pharma Co., Ltd. is a Chinese pharmaceutical company driven by independent research and development. In-house original research and innovation have always been its core strategy. The company established HEC Pharmaceutical Research Institute in 2005, focusing on three key therapeutic areas, including infectious diseases, chronic diseases, and oncology, the company committed to developing products with breakthrough potential. The company continues to improve and develop our research and development platform and enhance research and development capabilities, and has built a complete set of technology systems for the entire cycle of drug development from early drug discovery to commercialization and manufacture. The company is equipped with full-cycle research and development platforms for both chemical drugs and biologics. Simultaneously, the company is committed to applying AI technology across all stages of drug research and development, having established multiple advanced AI-driven models to enhance our innovation capabilities and development efficiency.

As of June 2025, the company had 150 approved drugs in various countries and regions, including China, the United States and Europe. the company also had more than 100 drugs in the pipeline, including 49 Class I innovative drug candidates in China. The company has successfully developed and launched three Class I innovative drugs and applied for launching one Class I innovative drug through in-house research and development.

2005

HEC Pharmaceutical Research Institute (year)
147

Commercialized Products (Number)
100

Self-Developed Pipeline (>Number)
10

Phase II/III Clinical Stage (Number)

HEC Pharmaceutical Research Institute

HEC Pharmaceutical Research Institute was established in 2005. Driven by the dual engines of "Innovation" and "Internationalization", it focuses on the global development and commercialization of innovative small molecule drugs, innovative biologics and biosimilars, and novel formulations including first generics, spanning multiple fields such as infectious diseases like hepatitis B and C, oncology like esophageal cancer, and endocrine and metabolic diseases like diabetes.

State Key Laboratory of Anti-Infective Drug Development

Approved by the Ministry of Science and Technology of the PRC in September 2015 as the " State Key Laboratory of Anti-Infective Drug Development" the laboratory underwent restructuring and upgrading in 2022, and was officially designated the "State Key Laboratory of Anti-Infective Drug Development" in 2023, with Sunshine Lake Pharma Co., Ltd. as its primary supporting institution. Current major research includes: persistent viral pathogenesis and novel drug development; emergent viral pathogenesis (e.g. COVID-19 virus) and novel drug development; bacterial resistance mechanisms and novel drug development; pathogenesis of infectious disease complications and novel drug development.

R&D Team

The company has developed comprehensive and integrated in-house research and development capabilities. The company has more than 1,100 research and development personnels which consist of scientists with extensive work experience gained in multinational pharmaceutical companies and pharmaceutical talents with rich experience in research and development.

Innovative Technology Platforms

The company regards innovation as a key driver for future development and has established an AIDD platform, a novel small molecule drug discovery platform, a peptide/antibody/fusion protein technology platform, a small interfering RNA (siRNA) drugs technology platform, a cell therapy technology platform, and an innovative formulation drug development platform. It remains focused on platforms upgrades to further diversify and robust drug pipeline for sustainable growth.

AIDD

Leveraging proprietary R&D data and cutting-edge algorithms, it has formed four core models: molecular screening, molecular generation, PBPK modeling, and retrosynthetic analysis, with its first discovered novel drug molecule HEC169584 approved for clinical trials.

Novel Small Molecule Drug Discovery Platform

Novel Small Molecule Drug Discovery Platform The company designs and optimizes differentiated candidate molecules with high clinical value, featuring three launched novel molecules, one novel molecule nearing launch, and over 30 candidates approved for clinical trials.

Peptide/Antibody/Fusion Protein Technology Platform

With mature protein expression systems, advanced antibody screening and engineering technologies, and comprehensive solid-phase peptide synthesis capabilities, the company has launched five insulin products, with one insulin product nearing approval in the US, multi-target GLP-1 drugs, and the world's first bispecific antibody.

Small Interfering RNA (siRNA) Drugs Technology Platform

The company has established an integrated platform encompassing sequence design/screening, bioanalysis, monomer modification, vector design/synthesis, and nucleic acid synthesis/purification. Its first siRNA drug candidate is about to file for clinical trial application.

Cell Therapy Technology Platform

The company has developed proprietary technologies including pluripotent stem cell directed differentiation and an innovative rapid CAR-T viral vector platform.

Innovative Formulation Drug Development Platform

The company possesses four core technologies: soft mist inhalation, long-acting injectables, oral sustained-release systems, and prodrug formulation modifications, focusing on pediatric and geriatric drug development. It has submitted its first NDA for an improved new drug and has three candidates in clinical trials.